<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gadoterate meglumine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gadoterate meglumine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Gadoterate meglumine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="96840" href="/d/html/96840.html" rel="external">see "Gadoterate meglumine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="103674" href="/d/html/103674.html" rel="external">see "Gadoterate meglumine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F16424023"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Nephrogenic systemic fibrosis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Gadolinium-based contrast agents (GBCAs) increase the risk of nephrogenic systemic fibrosis among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with noncontrasted magnetic resonance imaging (MRI) or other modalities. Nephrogenic systemic fibrosis may result in fatal or debilitating fibrosis affecting the skin, muscle, and internal organs. The risk of nephrogenic systemic fibrosis appears highest among patients with chronic, severe kidney disease (glomerular filtration rate [GFR] &lt;30 mL/minute/1.73 m<sup>2</sup>) or acute kidney injury. Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk of chronically reduced renal function (eg, age &gt;60 years, hypertension, diabetes), estimate the GFR through laboratory testing. For patients at highest risk of nephrogenic systemic fibrosis, do not exceed the recommended dose, and allow a sufficient period of time for elimination of the drug from the body prior to any readministration.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F21879247"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Clariscan;</li>
<li>Dotarem</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871588"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Dotarem</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F16424027"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Diagnostic Agent;</li>
<li>
                        Gadolinium-Containing Contrast Agent;</li>
<li>
                        Macrocyclic Gadolinium-Based Contrast Agent;</li>
<li>
                        Radiological/Contrast Media (Ionic);</li>
<li>
                        Radiological/Contrast Media, Paramagnetic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F21879444"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="800bae13-16dc-4a0e-adc3-edd65ef3b79d">CNS imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>CNS imaging:</b> IV: 0.2 mL/kg (0.1 mmol/kg); may begin imaging immediately after administration.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990729"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">No dosage adjustment recommended; however, use with caution. The risk for developing nephrogenic systemic fibrosis (NSF) increases as renal function decreases.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Gadoterate meglumine is removed by hemodialysis.</p></div>
<div class="block doha drugH1Div" id="F50988095"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F21879453"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F21879443"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="103674" href="/d/html/103674.html" rel="external">see "Gadoterate meglumine: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing presented in mL/kg and mmol/kg; use precaution. Parenteral solution contains 0.5 mmol/mL of gadoterate meglumine.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ce1563e3-2b26-4194-a933-5a3736125306">CNS magnetic resonance imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>CNS magnetic resonance imaging:</b> Infants, Children, and Adolescents: IV: 0.2 mL/kg (0.1 mmol/kg); may begin imaging immediately after administration.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51112222"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer's labeling; however, use with caution; acute kidney injury requiring dialysis has been reported with use in patients with chronic renal dysfunction; risk may be increased with higher doses of contrast agent. Risk for nephrogenic systemic fibrosis (NSF) development increases as renal function decreases.</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: Gadoterate meglumine is removed by hemodialysis.</p></div>
<div class="block dohp drugH1Div" id="F51112223"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F21964157"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (≤1)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Altered sense of smell, anaphylactoid reaction, anaphylaxis, angioedema, anxiety, bradycardia, bronchospasm, burning sensation, cardiac arrest, cardiac arrhythmia, circulatory shock, coma, conjunctivitis, convulsions, cyanosis, diarrhea, dizziness, drowsiness, dysgeusia, eyelid edema, fatigue, feeling hot, fever, hyperhidrosis, hypersensitivity reaction, hypertension, hypotension, increased lacrimation, increased serum creatinine, inflammation at injection site, injection site pruritus, injection site reaction (including cold, warmth), laryngeal discomfort, laryngospasm, limb pain, malaise, muscle spasm, myasthenia, ocular hyperemia, pain, pain at injection site, palpitations, paresthesia, pharyngeal edema, phlebitis (superficial), presyncope, pruritus, respiratory arrest, sensation of cold, sialorrhea, skin rash, swelling at injection site, syncope, tachycardia, tremor, urticaria, vomiting, weakness</p></div>
<div class="block coi drugH1Div" id="F21879301"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to gadoterate meglumine or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications not in US labeling: Subarachnoid or epidural administration</p></div>
<div class="block war drugH1Div" id="F21879319"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: May be a vesicant (higher osmolar contrast agents and/or higher volumes are associated with a higher risk). Ensure proper needle or catheter placement prior to and during administration. Monitor infusion site. Avoid extravasation; local tissue irritation may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gadolinium retention: Gadolinium is retained for months or years in brain, bone, skin, and other organs (kidney, liver, spleen); the highest concentration and longest duration have been found in the bone. Linear GBCAs (gadodiamide and gadoversetamide &gt; gadoxetate disodium, gadopentetate dimeglumine, and gadobenate dimeglumine) result in more retention than macrocyclic GBCAs (gadoterate meglumine, gadobutrol, and gadoteridol). Pathologic and clinical consequences of gadolinium retention in skin and other organs have been established in patients with impaired renal function; there also have been rare reports of pathologic skin changes in patients with normal renal function. Consequences of gadolinium retention in the brain or in patients with normal renal function have not been established. Patients with normal renal function that may be at higher risk for gadolinium retention include: patients requiring multiple lifetime doses, pregnant and pediatric patients, and patients with inflammatory conditions; take GBCA retention characteristics into consideration for these patients. Minimize repetitive GBCA imaging studies.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Anaphylactic and anaphylactoid reactions have occurred (with cardiovascular, respiratory, or dermatologic involvement); some have involved fatalities due to circulatory collapse. Symptoms typically occurred within minutes of administration and resolved with prompt emergency treatment. Prior to administration, assess patients for history of contrast media reaction, bronchial asthma, and/or allergic disorders. Monitor patients closely during and after infusion. If hypersensitivity occurs, begin immediate management. Appropriate equipment, trained personnel and emergency medications should be available during use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrogenic systemic fibrosis: <b>[US Boxed Warning]: Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) in patients with impaired elimination of the agents; avoid use unless GBCA enhanced imaging is essential for diagnostic purposes. The risk is highest in patients with acute kidney injury or chronic, severe renal disease (GFR &lt;30 mL/minute/1.73 m<sup>2</sup>). NSF may result in debilitating or fatal systemic fibrosis affecting the skin, muscle, and internal organs. Prior to administration, screen all patients for acute kidney injury or other conditions which may reduce renal function; estimate glomerular filtration rate in patients at risk for chronic declines in renal function (eg, age &gt;60, chronic hypertension, diabetes). Do not exceed the recommended dose and allow a sufficient interval between readministration in patients at risk for NSF.</b> The risk for NSF appears lower in patients with chronic moderate renal disease (GFR 30 to 59 mL/minute/1.73 m<sup>2</sup>) and little, if any, in patients with chronic mild renal disease (GFR 60 to 89 mL/minute/1.73 m<sup>2</sup>). In patients receiving hemodialysis, consider prompt initiation of hemodialysis following administration. If NSF occurs, report to manufacturer or the Food and Drug Administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Dose-dependent acute kidney injury has occurred in patients with chronic renal insufficiency following use of gadolinium agents; administer the lowest dose necessary for adequate imaging. Evaluate renal function in all patients; consider follow-up assessment of renal function in patients with a history of renal dysfunction.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878788"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Pediatric patients may experience a higher incidence of headache than adults.</p></div>
<div class="block foc drugH1Div" id="F22901339"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Clariscan: 5 mmol/10 mL (10 mL); 7.5 mmol/15 mL (15 mL); 10 mmol/20 mL (20 mL); 50 mmol/100 mL (100 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dotarem: 5 mmol/10 mL (10 mL); 7.5 mmol/15 mL (15 mL); 10 mmol/20 mL (20 mL); 50 mmol/100 mL (100 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mmol/5 mL (5 mL); 5 mmol/10 mL (10 mL); 7.5 mmol/15 mL (15 mL); 10 mmol/20 mL (20 mL); 50 mmol/100 mL (100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Clariscan: 2.5 mmol/5 mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dotarem: 2.5 mmol/5 mL (5 mL); 5 mmol/10 mL (10 mL); 7.5 mmol/15 mL (15 mL); 50 mmol/100 mL (100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dotarem: 5 mmol/10 mL (10 mL); 7.5 mmol/15 mL (15 mL); 10 mmol/20 mL (20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Clariscan: 5 mmol/10 mL (10 mL); 7.5 mmol/15 mL (15 mL); 10 mmol/20 mL (20 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dotarem: 5 mmol/10 mL (10 mL); 7.5 mmol/15 mL (15 mL)</p></div>
<div class="block geq drugH1Div" id="F21879258"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F23613357"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Clariscan Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5MMOL/5ML (per mL): $6.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mmol/10 mL (per mL): $6.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mmol/15 mL (per mL): $6.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mmol/20 mL (per mL): $6.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mmol/100 mL (per mL): $6.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Dotarem Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5MMOL/5ML (per mL): $6.36</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mmol/10 mL (per mL): $3.96</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mmol/15 mL (per mL): $3.36</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mmol/20 mL (per mL): $3.36</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mmol/100 mL (per mL): $3.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Gadoterate Meglumine Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5MMOL/5ML (per mL): $4.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mmol/10 mL (per mL): $2.77</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mmol/15 mL (per mL): $2.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mmol/20 mL (per mL): $2.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mmol/100 mL (per mL): $2.17</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Clariscan Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mmol/10 mL (per mL): $6.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mmol/15 mL (per mL): $6.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mmol/20 mL (per mL): $6.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Dotarem Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mmol/10 mL (per mL): $4.63</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mmol/15 mL (per mL): $3.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mmol/20 mL (per mL): $3.60</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871589"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dotarem: 376.9 mg/mL (5 mL, 10 mL, 15 mL, 20 mL, 60 mL, 100 mL)</p></div>
<div class="block adm drugH1Div" id="F21879498"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Administer as an IV bolus injection (by manual injection or power injector). Infuse at a rate of approximately 2 mL/second. To ensure complete injection of contrast agent, flush line with NS after administration.</p>
<p style="text-indent:0em;margin-top:2em;">May be a vesicant (higher osmolar contrast media and higher volumes are associated with a higher risk); ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect; remove needle/cannula; elevate extremity. Aspiration of extravasated contrast media is not recommended (ACR 2023). Information conflicts regarding the use of hyaluronidase; the American College of Radiology (ACR) Manual on Contrast Media does not recommend hyaluronidase in the management of contrast media extravasation (ACR 2023); other sources suggest its utility in extravasation management for inoperable cases with compartment syndrome (Stefanos 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>If using hyaluronidase:</i>
<b>Intradermal or SUBQ:</b> Dose varies based on the size of infiltration; inject a total of 5 to 250 units (~100 mL contrast reabsorbed per 15 units of hyaluronidase) around the site of extravasation (Stefanos 2023).</p></div>
<div class="block admp drugH1Div" id="F52614532"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Administer as an IV bolus injection (by manual injection or power injector). To ensure complete injection of contrast agent, flush line with NS after administration.</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates, Infants, Children, and Adolescents: Infuse at a rate of 1 to 2 mL/second</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">May be a vesicant (higher osmolar contrast media and higher volumes are associated with a higher risk); ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect; remove needle/cannula; elevate extremity. Aspiration of extravasated contrast media is not recommended (ACR 2018). Information conflicts regarding the use of hyaluronidase; the American College of Radiology (ACR) Manual on Contrast Media does not recommend hyaluronidase in the management of contrast media extravasation (ACR 2018); other sources suggest its utility in extravasation management (Bellin 2002; Reynolds 2014) (see Management of Drug Extravasations for more details).</p></div>
<div class="block meg drugH1Div" id="F51378196"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Dotarem: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2018%2F204781s008lbl.pdf%23page%3D29&amp;token=duuIdM%2B1nCfp6QDralMDKH9KDRQXahyHLLFs3J8%2BGFNH84NbLxLHVXT0V01OZ9ZcnKKPyfrCQIrC3O6NjOC%2FQSy6vnCuS7Kuptt6zfU0GJzNfWZtfSlWYkUZEQCokk%2FU&amp;TOPIC_ID=88898" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204781s008lbl.pdf#page=29</a></p></div>
<div class="block use drugH1Div" id="F16424029"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>CNS imaging:</b> Contrast medium for magnetic resonance imaging (MRI) in adults, adolescents, and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity in the brain (intracranial), spine, and associated tissues</p></div>
<div class="block cyt drugH1Div" id="F24674118"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F24674115"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F21879279"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Gadolinium-based contrast agents may cross the placenta (ACOG 723 2017; ACR 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Pregnant patients may be at increased risk for gadolinium retention. Use of gadolinium-based contrast agents in pregnancy is controversial and should be limited. A gadolinium-based contrast agent with MRI may be considered for use in pregnancy if it will significantly improve diagnostic performance and is expected to improve fetal or maternal outcome (ACOG 723 2017). In addition, use should only be considered if information needed from the MRI study cannot be acquired without using a contrast agent and cannot be deferred until after delivery. Agents with a low risk for development of nephrogenic systemic fibrosis should be used at the lowest effective dose (ACR 2018).</p></div>
<div class="block brc drugH1Div" id="F21879300"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Gadolinium-based contrast agents may be present in breast milk (ACOG 723 2017; ACR 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Because of the low expected excretion into breast milk and the low absorption from an infant's GI tract, breastfeeding may be continued without interruption after use (ACOG 723 2017; ACR 2018). Theoretically, the taste of milk could be altered if it contains contrast media. Women who prefer to temporarily withhold breastfeeding may express and discard milk from both breasts during a period of 12 to 24 hours after the administration of contrast media. They can pump and store milk prior to the procedure then bottle feed using the stored milk during this time (ACR 2018). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F21879502"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs of hypersensitivity (during and after administration); renal function (prior to administration); signs/symptoms of NSF (eg, burning, itching, swelling, hardening and/or tightening of skin, joint stiffness, deep hip or rib bone pain, muscle weakness, limited range of motion, and/or yellowed/raised spots on whites of eye); monitor injection site for signs/symptoms of extravasation</p></div>
<div class="block pha drugH1Div" id="F21879402"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Gadoterate meglumine is a gadolinium-containing paramagnetic macrocyclic ionic contrast agent. Exposure to an external magnetic field induces a local magnetic moment in exposed tissues. This local magnetism enhances water proton relaxation in the vicinity, resulting in an increase in signal intensity (brightness) in tissues. Does not cross intact blood-brain barrier, therefore will only enhance brain lesions if the blood-brain barrier is disrupted or if there is abnormal vascularity.</p></div>
<div class="block phk drugH1Div" id="F21879418"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Imaging may begin immediately after administration</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: 179 ± 26 mL/kg (female); 211 ± 35 mL/kg (male); does not cross intact blood-brain barrier</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: None</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Not metabolized</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 1.4 ± 0.2 hours (female); 2 ± 0.7 hours (male)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (72.9% ± 17% female; 85.4 ± 9.7% male)</p></div>
<div class="block phksp drugH1Div" id="F51196084"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Following a single 0.1 mmol/kg dose to patients with creatinine clearances of 10-60 mL/minute, gadolinium elimination was delayed. Total clearance decreased in correlation with the degree of renal impairment. Cumulative urinary excretion was ~77% over 48 hours in patients with moderate impairment and ~68% over 72 hours in patients with severe impairment, compared to ~93% over 24 hours in patients with normal renal function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F23777443"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Dotarem</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Clariscan | Cyclolux | Dotagraf | Dotarem</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Dotarem</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Clariscan | Dotagraph | Dotarem</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Clariscan</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Dotarem</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Clariscan | Dotagraf</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Dotarem</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Clariscan | Dotarem</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Clariscan | Dotarem</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Clariscan | Cyclolux | Dota mr | Dotagita | Dotagraf | Dotarem | Dotavision | Gadotersaeure agfa</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Clariscan</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Dotarem</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Clariscan | Dotarem</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Clariscan | Dotarem</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Artirem | Clariscan | Dotarem</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Dotarem</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cyclolux | Dotarem</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Dotarem</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Clariscan | Dotarem</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Clariscan | Cyclolux | Dotagraf</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Dotavist</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Claricyclic | Dotarem</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Magnescope</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Clariscan | Dotarem | Uniray</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Clariscan</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Dotarem</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Dotarem</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Clariscan | Dotagraf | Dotarem</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Clariscan | Dotarem</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Dotarem</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Dotarem</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Clariscan | Dotarem</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Dotarem</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Dotarem</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Dotarem</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Dotarem</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Clariscan | Dotarem</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Clariscan</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Clariscan | Dotarem</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Dotarem</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Dotarem</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Dotarem</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Clariscan</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-26942391">
<a name="26942391"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee Opinion No. 656: guidelines for diagnostic imaging during pregnancy and lactation. <i>Obstet Gynecol</i>. 2016;127(2):e75-e80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadoterate-meglumine-drug-information/abstract-text/26942391/pubmed" id="26942391" target="_blank">26942391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28937575">
<a name="28937575"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee Opinion No. 723: guidelines for diagnostic imaging during pregnancy and lactation. <i>Obstet Gynecol</i>. 2017;130(4):e210-e216. Erratum in: <i>Obstet Gynecol</i>. 2018;132(3):786.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadoterate-meglumine-drug-information/abstract-text/28937575/pubmed" id="28937575" target="_blank">28937575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACR.1">
<a name="ACR.1"></a>American College of Radiology (ACR) Committee on Drugs and Contrast Media. ACR manual on contrast media. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf. Published April 2023. Accessed May 17, 2023.</div>
</li>
<li>
<div class="reference">
                  American College of Radiology (ACR), North American Society for Cardiovascular Imaging (NASCI), Society for Pediatric Radiology (SPR). ACR-NASCI-SPR practice guideline for the performance of pediatric and adult body magnetic resonance angiography (MRA). [online publication]. Reston (VA): American College of Radiology (ACR); 2010. 16 p. Available at: http://www.acr.org/~/media/D1BC4FB23D4B4005872FDDAE018E0CE7.pdf. Accessed December 21, 2014.</div>
</li>
<li>
<div class="reference">
                  American College of Radiology (ACR), Society for Pediatric Radiology (SPR). ACR-SPR Practice Parameter for the Use of Intravascular Contrast Media. [online publication]. Reston (VA): American College of Radiology (ACR); 2012. 7 p. Available at: http://www.acr.org/~/media/536212D711524DA5A4532407082C89BA.pdf. Accessed December 21, 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21890295">
<a name="21890295"></a>Anzalone N, Scarabino T, Venturi C, et al. Cerebral neoplastic enhancing lesions: multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1 mmol Gd/kg body weight in a clinical setting. <i>Eur J Radiol</i>. 2013;82(1):139-145.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadoterate-meglumine-drug-information/abstract-text/21890295/pubmed" id="21890295" target="_blank">21890295</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12386778">
<a name="12386778"></a>Bellin MF, Jakobsen JA, Tomassin I, et al; Contrast Media Safety Committee Of The European Society Of Urogenital Radiology. Contrast medium extravasation injury: guidelines for prevention and management. <i>Eur Radiol</i>. 2002;12(11):2807-2812. doi: 10.1007/s00330-002-1630-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadoterate-meglumine-drug-information/abstract-text/12386778/pubmed" id="12386778" target="_blank">12386778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Clariscan.1">
<a name="Clariscan.1"></a>Clariscan (gadoterate meglumine) [prescribing information]. Marlborough, MA: GE Healthcare Inc; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dotarem.1">
<a name="Dotarem.1"></a>Dotarem (gadoterate meglumine) [prescribing information]. Princeton, NJ: Guerbet LLC; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dotarem.2">
<a name="Dotarem.2"></a>Dotarem (gadoterate meglumine) [product monograph]. Brantford, Ontario, Canada: July 2023.</div>
</li>
<li>
<div class="reference">
                  Dotarem pharmacy bulk package (gadoterate meglumine) [prescribing information]. Princeton, NJ: Guerbet LLC; April 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23345200">
<a name="23345200"></a>Expert Panel on MR Safety, Kanal E, Barkovich AJ, et al. ACR guidance document on MR safe practices: 2013. <i>J Magn Reson Imaging</i>. 2013;37(3):501-530.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadoterate-meglumine-drug-information/abstract-text/23345200/pubmed" id="23345200" target="_blank">23345200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19128909">
<a name="19128909"></a>Janus N, Launay-Vacher V, Karie S, et al. Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study. <i>Eur J Radiol</i>. 2010;73(2):357-359.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadoterate-meglumine-drug-information/abstract-text/19128909/pubmed" id="19128909" target="_blank">19128909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6628223">
<a name="6628223"></a>MacCara ME. Extravasation: a hazard of intravenous therapy. <i>Drug Intell Clin Pharm</i>. 1983;17(10):713-717.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadoterate-meglumine-drug-information/abstract-text/6628223/pubmed" id="6628223" target="_blank">6628223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22871150">
<a name="22871150"></a>Meng H, Grosse-Wortmann L. Gadolinium in pediatric cardiovascular magnetic resonance: what we know and how we practice. <i>J Cardiovasc Magn Reson</i>. 2012;14:56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadoterate-meglumine-drug-information/abstract-text/22871150/pubmed" id="22871150" target="_blank">22871150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-32. doi: 10.1002/phar.1396.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadoterate-meglumine-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22633726">
<a name="22633726"></a>Rowlett J. Extravasation of contrast media managed with recombinant human hyaluronidase. <i>Am J Emerg Med</i>. 2012;30(9):2102.e1-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadoterate-meglumine-drug-information/abstract-text/22633726/pubmed" id="22633726" target="_blank">22633726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy</i>. 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadoterate-meglumine-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22403117">
<a name="22403117"></a>Tremblay E, Thérasse E, Thomassin-Naggara I, et al. Quality initiatives: guidelines for use of medical imaging during pregnancy and lactation. <i>Radiographics</i>. 2012;32(3):897-911.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadoterate-meglumine-drug-information/abstract-text/22403117/pubmed" id="22403117" target="_blank">22403117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22451541">
<a name="22451541"></a>Wang PI, Chong ST, Kielar AZ, et al. Imaging of pregnant and lactating patients: part 1, evidence-based review and recommendations. <i>AJR Am J Roentgenol</i>. 2012;198(4):778-784.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadoterate-meglumine-drug-information/abstract-text/22451541/pubmed" id="22451541" target="_blank">22451541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15609057">
<a name="15609057"></a>Webb JA, Thomsen HS, Morcos SK, et al. The use of iodinated and gadolinium contrast media during pregnancy and lactation. <i>Eur Radiol</i>. 2005;15(6):1234-1240.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadoterate-meglumine-drug-information/abstract-text/15609057/pubmed" id="15609057" target="_blank">15609057</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Zenk KE. Management of intravenous extravasations. <i>Infusion</i>. 1981;5(4):77-79.</div>
</li></ol></div><div id="topicVersionRevision">Topic 88898 Version 170.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
